PCI Pharma Services announced on July 14, 2025 that it has received a strategic investment co-led by Bain Capital and Kohlberg, the current lead investor, and supported by a significant reinvestment from Mubadala Investment Company ("Mubadala"). Partners Group will also continue to support the company with a minority stake.

Bain Capital and Kohlberg are investing several billion dollars in PCI Pharma Services, valuing the Philadelphia-based CDMO at $10 billion, including debt, according to a report by the Wall Street Journal.

PCI provides provide Sterile and High Potent Drug Development, Clinical Trial Services, and Commercial Packaging for the pharmaceutical and biopharmaceutical sector. Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle.

PCI brings the proven experience that comes with more than 450 successful product launches over the last five years and over 50 years in pharmaceutical services helping bring to life innovation to improve patient access and outcomes.

The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients.

Kohlberg and Mubadala, both of which initially invested in PCI in 2020, and Bain Capital are partnering with PCI's management team, led by Chief Executive Officer Salim Haffar, to accelerate the Company's growth trajectory, build upon its strong customer service experience, and further enable PCI clients to bring life-changing biopharmaceutical therapies to market. PCI will primarily focus on organic and inorganic growth initiatives, including expanding its suite of services and geographic reach. Leveraging global growth trends in biologics and specialized drug therapies, PCI's future investments will include expansion of existing sterile fill-finish of injectables and high potent and specialized manufacturing capacity. The strategic investment will also enable the Company's significant continued investment in the US, bolstering the nation's critical pharmaceutical manufacturing and supply chain infrastructure.

Haffar said: "PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions. I am grateful for the ongoing support of our existing investors and enthusiastically welcome Bain Capital and their deep, global healthcare and life science capabilities and expertise. Together we will grow PCI's commercial, clinical trial services, and development and manufacturing businesses to meet the future demands of our biopharmaceutical customers."

Matt Jennings, Chairman of PCI and an Operating Partner of Kohlberg, commented: "PCI's world-class management team, combined with the support of experienced industry investors, has proven to be a very successful formula. We are delighted for Bain Capital to join PCI's investor base, yielding an optimal combination aligned to support Salim and the management team to execute on their growth ambitions and value creation pathways."

Devin O'Reilly, Partner at Bain Capital, said: "Anchored by an innovative, advanced platform that is consistently growing and setting new standards for the industry, PCI Pharma has built a well-deserved reputation as a differentiated partner to leading biopharma companies, ensuring critical therapies reach patients safely and efficiently. We look forward to working alongside Kohlberg to build on this strong foundation."

Andrew Kaplan and Christina Dix, Partners at Bain Capital added: "We are excited to leverage our industry expertise and the collaboration of our global healthcare team to support Salim and PCI's team of experienced industry leaders in the mission to drive innovation in advanced pharmaceutical services that improve patients' lives and outcomes."

Chris Anderson, Senior Partner of Kohlberg, added: "We are honored to have supported PCI's transformation over the last five years into a leading global CDMO, positioned in the fastest growing markets and known for its proven experience meeting critical customer needs throughout the drug development and commercialization lifecycle. We are thrilled to be partnering with Bain Capital and are aligned to make new investments that will further elevate the Company's capabilities and growth for many years to come."

Mina Hamoodi, Head of Healthcare at Mubadala, said: "Our reinvestment in PCI reflects our deep conviction in the company's mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner. We look forward to partnering with Bain and Kohlberg, and working closely with PCI's outstanding management team, as the company enters its next chapter of accelerated growth."